NASDAQ: INDV - Indivior PLC

Rentabilité sur six mois: -18.93%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Indivior PLC


À propos de l'entreprise Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd.

plus de détails
The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

IPO date 2014-12-29
ISIN GB00BN4HT335
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 12.24
Дивиденд ао 0.475
Сайт https://www.indivior.com
Цена ао 8.71
Changement de prix par jour: +0.487% (12.32)
Changement de prix par semaine: +6.17% (11.66)
Changement de prix par mois: +9.27% (11.33)
Changement de prix sur 3 mois: +23.31% (10.04)
Changement de prix sur six mois: -18.93% (15.27)
Changement de prix par an: -18.93% (15.27)
Evolution du prix sur 3 ans: +1 792.97% (0.654)
Evolution du prix sur 5 ans: +12 959.07% (0.0948)
Evolution des prix sur 10 ans: 0% (12.38)
Evolution des prix depuis le début de l'année: +18.41% (10.455)

Sous-estimation

Nom Signification Grade
P/S 1.91 7
P/BV 58.87 1
P/E 1067.05 1
EV/EBITDA 7.17 9
Total: 5.88

Efficacité

Nom Signification Grade
ROA, % 0.1025 1
ROE, % 2.95 1
Total: 3.5

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0.6667 6.67
Total: 4.22

Devoir

Nom Signification Grade
Debt/EBITDA 0.8467 9
Total: 7.8

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 39.24 5
Rentabilité Ebitda, % -70.17 0
Rentabilité EPS, % -98.46 0
Total: 1

Établissements Volume Partager, %
Two Seas Capital LP 13670312 9.96
Scopia Capital Management LP 8311367 6.06
Vanguard Group Inc 5846354 4.26
Goldman Sachs Group Inc 5683038 4.14
FMR, LLC 5498087 4.01
Artemis Investment Management LLP 3127399 2.28
Bank of America Corporation 2701855 1.97
Polar Capital Holdings PLC 2621150 1.91
Acadian Asset Management. LLC 2281179 1.66
Liontrust Investment Partners LLP 1995889 1.45



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Mark Crossley CEO & Executive Director 2.34M
Mr. Ryan Preblick CFO & Executive Director 1.14M
Dr. Christian Heidbreder Chief Scientific Officer N/A
Mr. Jason Thompson Vice President of Investor Relations N/A
Ms. Cynthia Cetani Chief Integrity & Compliance Officer N/A
Mr. Jeffrey W. Burris Chief Legal Officer N/A 1972 (53 année)
Mr. Jon Fogle Chief Human Resources Officer N/A
Mr. Richard Simkin Chief Commercial Officer N/A
Mr. Hillel West Chief Manufacturing & Supply Officer N/A
Mr. Vishal Kalia SVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy Officer N/A

Adresse: United States, North Chesterfield. VA, 10710 Midlothian Turnpike - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.indivior.com